Close Menu

Agilent

News items for the in vitro diagnostics industry for the week of March 15, 2021.

The Agilent SARS-CoV-2 qRT-PCR Dx kit detects N1 and N2 targets from SARS-CoV-2 RNA isolated and purified from nasopharyngeal swab specimens.

The firm will build liquid biopsy companion diagnostic tests that complement its tissue-based assays and are tailored for drugs developed by pharma partners.

The firm plans to use the proceeds to fund the redemption of senior notes due in 2022 and for general corporate purposes.

Under the deal, expected to close in April, Agilent will pay $550 million in cash on closing and up to an additional $145 million based on future milestones.

The test relies on a spermine risk score coupled with a urine test to predict which patients are most likely to have prostate cancer.

Advanced NSCLC patients must have a PD-L1 expression tumor proportion score of 50 percent, and no EGFR, ALK, or ROS1 alterations, to receive the drug.

For the three months ended Jan. 31, the firm said revenues rose to $1.55 billion from $1.36 billion a year ago, beating analysts' average estimate of $1.44 billion.

The diagnostic is composed of Agilent's Bravo automation workstation and Mammoth's DETECTR BOOST SARS-CoV-2 assay.

Qiagen discussed what's in store after a failed bid by Thermo Fisher Scientific, and COVID-19 remained a hot topic on the second day of the virtual conference.

Pages